ICD-10 Coding for Elevated Prostate Specific Antigen(R79.8, R79.8U, R97.2)
Learn about ICD-10 coding for elevated prostate specific antigen, including code R97.20 for elevated PSA without malignancy and Z12.5 for screening.
Complete code families applicable to Elevated Prostate Specific Antigen
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| R97.20 | Elevated prostate specific antigen [PSA] | Use when PSA levels are elevated without a confirmed diagnosis of prostate cancer. |
|
| Z12.5 | Encounter for screening for malignant neoplasm of prostate | Use for routine screening encounters without prior PSA elevation. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutElevated Prostate Specific Antigen
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Elevated Prostate Specific Antigen.
Failing to document PSA value
Impact
Clinical: Inadequate clinical information for decision-making., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials due to lack of medical necessity.
Mitigation
Always include PSA values in documentation., Use templates to ensure completeness.
Using Z12.5 with R97.20 for diagnostic follow-up
Impact
Reimbursement: Claims may be denied if Z12.5 is used incorrectly., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate data on screening vs. diagnostic encounters.
Mitigation
Use R97.20 alone for diagnostic follow-up of elevated PSA.
PSA Value Documentation
Impact
High audit risk if PSA values are not documented.
Mitigation
Implement mandatory fields in EHR for PSA values.